Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Patients with metastatic solid tumors who had progressed on at least one line of standard of care therapy were referred to the Indiana University Health Precision Genomics Program. Tumor samples were submitted for DNA & RNA next-generation sequencing, fluorescence in situ hybridization, and immu...

Ausführliche Beschreibung